{"entity":{"id":"pbld","kind":"target","name":"PBLD","aka":["phenazine biosynthesis like protein domain containing","Phenazine biosynthesis-like domain-containing protein","MAWBP","MAWDBP","FLJ14767"],"tldr":"PBLD (Phenazine biosynthesis-like domain-containing protein) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Hepatocellular carcinoma.","summary":"Functions as a positive regulator of the antiviral immune response by modulating innate immunity and viral replication by enhancing type I interferon (IFN-I) response. PBLD enhances IFN-I signalling via multiple pathways. Promotes IRF3-mediated IFN-I production and apoptosis, thereby inhibiting viral replication.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:23301","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23301"},{"label":"UniProt P30039","url":"https://www.uniprot.org/uniprotkb/P30039/entry"},{"label":"NCBI Gene 64081","url":"https://www.ncbi.nlm.nih.gov/gene/64081"},{"label":"Ensembl ENSG00000108187","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108187"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PBLD","role":["biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:23301","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:23301","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P30039","url":"https://www.uniprot.org/uniprotkb/P30039/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene PBLD","url":"https://civicdb.org/features/14284","note":"1 evidence items, 0 assertions, 1 variants; diseases: Hepatocellular Carcinoma (GraphQL API, CC0)"}],"hgnc":"HGNC:23301","ensembl":"ENSG00000108187","uniprot":"P30039","entrez":"64081","biology":"Functions as a positive regulator of the antiviral immune response by modulating innate immunity and viral replication by enhancing type I interferon (IFN-I) response. PBLD enhances IFN-I signalling via multiple pathways. Promotes IRF3-mediated IFN-I production and apoptosis, thereby inhibiting viral replication. Up-regulates IFN-I response by activating the NF-kappaB signalling pathway, potentially through inhibition of TRIM21-mediated degradation of phosphorylated IKKbeta, thereby sustaining NF-kappaB activation to counteract viral infection. Additionally, promotes the p53-USP4-MAVS signalling axis by stabilising MAVS through USP4-mediated deubiquitination, thereby enhancing the IFN-I response against RNA virus infection. Acts as a tumour suppressor, regulating development of various cancers. Locus 10q21.3 (HGNC).","whereFound":["Hepatocellular carcinoma: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/pbld/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"}]}}